139 related articles for article (PubMed ID: 25828518)
1. CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.
Guo M; Alumkal J; Drachova T; Gao D; Marina SS; Jen J; Herman JG
Discov Med; 2015 Mar; 19(104):151-8. PubMed ID: 25828518
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
[TBL] [Abstract][Full Text] [Related]
4. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
[TBL] [Abstract][Full Text] [Related]
5. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
6. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
9. [Promoter region methylation of DNA damage repair genes in human gastric cancer].
Guo H; Yan W; Yang Y; Guo M
Zhonghua Yi Xue Za Zhi; 2014 Jul; 94(28):2193-6. PubMed ID: 25331470
[TBL] [Abstract][Full Text] [Related]
10. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
Safar AM; Spencer H; Su X; Coffey M; Cooney CA; Ratnasinghe LD; Hutchins LF; Fan CY
Clin Cancer Res; 2005 Jun; 11(12):4400-5. PubMed ID: 15958624
[TBL] [Abstract][Full Text] [Related]
13. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
[TBL] [Abstract][Full Text] [Related]
14. Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.
Huang X; Wu C; Fu Y; Guo L; Kong X; Cai H
Bull Cancer; 2018 Sep; 105(9):746-754. PubMed ID: 30126609
[TBL] [Abstract][Full Text] [Related]
15. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
16. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.
Mariatos G; Bothos J; Zacharatos P; Summers MK; Scolnick DM; Kittas C; Halazonetis TD; Gorgoulis VG
Cancer Res; 2003 Nov; 63(21):7185-9. PubMed ID: 14612512
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.
De Jong WK; Verpooten GF; Kramer H; Louwagie J; Groen HJ
Anticancer Res; 2009 Jan; 29(1):363-9. PubMed ID: 19331174
[TBL] [Abstract][Full Text] [Related]
18. Serum DNA as a tool for cancer patient management.
Ramirez JL; Taron M; Balaña C; Sarries C; Mendez P; de Aguirre I; Nuñez L; Roig B; Queralt C; Botia M; Rosell R
Rocz Akad Med Bialymst; 2003; 48():34-41. PubMed ID: 14737938
[TBL] [Abstract][Full Text] [Related]
19. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.
Corn PG; Summers MK; Fogt F; Virmani AK; Gazdar AF; Halazonetis TD; El-Deiry WS
Carcinogenesis; 2003 Jan; 24(1):47-51. PubMed ID: 12538348
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
